A Radomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of ocrelizumab in comparison to interferon Beta-1a (Rebif) in patients with relapsing Multiple Sclerosis.
Laufzeit: 01.01.2012 - 31.12.2014
Kurzfassung
MR Imaging enrolled in the above mentioned, doubleblind, placebo-controlled clinical trail. The focus is the effectivity and security of Teriflunomid in comparison with the therapy with Interferon-beta in multiple sclerosis.
